Table 1. Clinical characteristics of the SHCS cohort.
| Glu88Ter (homozygous and heterozygous) | Glu88 (homozygous) | ||
|---|---|---|---|
| Male n; (%) | 65 (74.7%) | 2835 (77.7%) | |
| Female n; (%) | 22 (25.3%) | 808 (22.3%) | |
| Age median; (IQR) | 46 (41–50) | 47 (41–53) | |
| Caucasian n; (%) | 80 (94.1%) | 3447 (95.3%) | |
| Peak viremia median; (IQR) | 168,423 (42,036; 440,051) | 103,094 (31,314; 290,000) | |
| CD4 nadir median; (IQR) | 236 (118; 306) | 225 (121; 323) | |
| Mode of HIV-1 acquisition n; (%) | |||
| Heterosexual | 25 (29.4%) | 1,116 (30.7%) | |
| Homosexual | 39 (45.9%) | 1,617 (44.7%) | |
| Intravenous drug user | 20 (23.5%) | 764 (21.1%) | |
| Other/unknown | 1 (1.2%) | 120 (3.3%) |
IQR, interquartile range.